2nd phase of 'Covaxin' to take place in Bhubaneswar's SUM Hospital in September and will use healthy volunteers
Guwahati: With the first phase of the human clinical trials of India’s indigenous COVID-19 vaccine, Covaxin, giving a green signal for being safe to use -- the second phase will now be conducted by the Institute of Medical Sciences (IMS) and Sum Hospital in Odisha's Bhubaneswar next week.
SUM Hospital was among the 12 sites from across the country selected for the human clinical trials of Covaxin. India’s indigenous potential vaccine for COVID-19 is developed by Hyderabad-based Bharat Biotech International.
The first phase involved 375 volunteers which included five in the Odisha facility. If reports are to be believed, there has been no complaints from the people who were administered the vaccine.
Dr E Venkat Rao, the principal investigator of the trials at SUM Hospital, said that the blood samples collected from the volunteers that received the vaccine are being collected to ascertain how effective Covaxin was and the level of antibodies developed.
According to him, they have already initiated the process for the second phase trial and is likely to be conducted after a week.
Reports said that many people have approached the hospital to volunteer for the second phase of the clinical trial. The volunteers will be screened thoroughly before being selected for the vaccine shots. Moreover, only healthy individuals will be selected for vaccine administration in the second round.
Though SUM Hospital has officially not yet divulged any details about the candidates who were vaccinated exactly a month ago, reports said that they did not experience any adverse effects after being vaccinated.
If the second phase of human clinical trials yields favourable results, the hospital will then go for the third phase. After the trials are completed, the vaccine is expected to be ready by 2021. Additionally, the Central Drugs Standard Control Organisation has also approved the skin trials of the vaccine, which was injected directly into the muscle during the first phase trial. Hence, along with the intramuscular route, Covaxin can be administered through the intradermal route as well.